

# Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Sabina Chiaretti,<sup>1\*</sup> Monica Messina,<sup>1,2\*</sup> Irene Della Starza,<sup>1,2</sup> Alfonso Piciocchi,<sup>2</sup> Luciana Cafforio,<sup>1</sup> Marzia Cavalli,<sup>1</sup> Akram Taherinasab,<sup>1</sup> Michela Ansuinelli,<sup>1</sup> Loredana Elia,<sup>1</sup> Guglielmo Albertini Petroni,<sup>1</sup> Roberta La Starza,<sup>3</sup> Martina Canichella,<sup>1</sup> Alessia Lauretti,<sup>1</sup> Maria Cristina Puzzolo,<sup>1</sup> Valentina Pierini,<sup>3</sup> Alessandra Santoro,<sup>4</sup> Orietta Spinelli,<sup>5</sup> Valerio Apicella,<sup>1</sup> Saveria Capria,<sup>1</sup> Francesco Di Raimondo,<sup>6</sup> Paolo De Fabritiis,<sup>7</sup> Cristina Papayannidis,<sup>8</sup> Anna Candoni,<sup>9</sup> Roberto Cairoli,<sup>10</sup> Marco Cerrano,<sup>11</sup> Nicola Fracchiolla,<sup>12</sup> Daniele Mattei,<sup>13</sup> Chiara Cattaneo,<sup>14</sup> Antonella Vitale,<sup>1</sup> Enrico Crea,<sup>2</sup> Paola Fazi,<sup>2</sup> Cristina Mecucci,<sup>3</sup> Alessandro Rambaldi,<sup>5</sup> Anna Guarini,<sup>15</sup> Renato Bassan<sup>16</sup> and Robin Foà<sup>1</sup>

<sup>1</sup>Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome; <sup>2</sup>GIMEMA Data Center, Fondazione GIMEMA Franco Mandelli Onlus, Rome; <sup>3</sup>Hematology and Bone Marrow Transplantation Unit, Department of Medicine, University of Perugia, Perugia; <sup>4</sup>Hematology and Bone Marrow Transplant Unit, Ospedali Riuniti Villa Sofia-Cervello, Palermo; <sup>5</sup>Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo; <sup>6</sup>Haematology Unit, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania; <sup>7</sup>Hematology Unit, S. Eugenio Hospital, Rome; <sup>8</sup>Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna; <sup>9</sup>Clinica di Ematologia e Unità di terapie Cellulari 'Carlo Melzi'-Azienda Sanitaria-Universitaria Integrata, Udine; <sup>10</sup>Hematology Unit, Niguarda Hospital, Milan; <sup>11</sup>Hematology Unit, Department of Oncology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Torino; <sup>12</sup>UOC Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano, Milan; <sup>13</sup>Department of Hematology, Ospedale S. Croce, Cuneo; <sup>14</sup>Department of Hematology, ASST Spedali Civili, Brescia; <sup>15</sup>Department of Molecular Medicine, Sapienza University, Rome and <sup>16</sup>Hematology Unit, Ospedale dell'Angelo and Ospedale Ss Giovanni e Paolo, Mestre, Venezia, Italy

\*SC and MM contributed equally as co-first authors.

©2021 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2020.247973

Received: January 24, 2020.

Accepted: May 20, 2020.

Pre-published: May 28, 2020.

Correspondence: SABINA CHIARETTI - chiaretti@bce.uniroma1.it

# **Ph-like ALL is associated with MRD persistence and poor outcome. First report from the MRD-oriented GIMEMA LAL1913 trial**

## **Supplementary Material and Methods**

### *MRD assessment*

- *Time points*

MRD was defined positive if  $\geq 10^{-4}$  for at least one IG-TR marker; it was evaluated at weeks 4 (time point (TP) 1), 10 (TP2), 16 (TP3) and 22 (TP4) with MRD results at week 10 (TP2) representing the earliest decisional TP.

- *IG/TR gene rearrangement detection*

Genomic DNA samples at diagnosis were screened by PCR amplification using the BIOMED-1 primer sets for Ig kappa deleting element gene rearrangements IGK-Kde, complete and incomplete TRD and TRG gene rearrangements.<sup>1</sup> Complete and incomplete IGH rearrangements were identified using 5 IGHV and 7 IGHD family primers in combination with one JH consensus primer according to BIOMED-2.<sup>2</sup> Similarly, for incomplete and complete TRB gene rearrangements, the respective BIOMED-2 multiplex PCR primer sets were used.<sup>2</sup> For TRD/A gene rearrangements, multiplex PCR primer sets were used.<sup>3</sup> The products obtained from Ig and TCR gene rearrangements were further examined by heteroduplex analysis to discriminate between amplifications derived from monoclonal or polyclonal lymphoid cell populations.<sup>4,5</sup> Biclonal or biallelic PCR products were separated either by cutting out amplicons from the polyacrylamide gel or by DNA cloning.

- *Sequencing and gene analysis*

The PCR products were directly sequenced using the Big Dye Terminator Cycle Sequencing Reaction Kit and analyzed using an automatic ABI PRISM 3130 DNA genetic analyzer (Applied Biosystems, Foster City, CA). The IGH, IGK, TRA TRB, TRD and TRG nucleotide sequences obtained were aligned to the IgBLlast data base (<http://www.ncbi.nlm.nih.gov/igblast/>, National Cancer for Biotechnology Information, Bethesda, MD) and to the international ImMunoGeneTics information system ([www.imgt.org](http://www.imgt.org), Initiator and Coordinator: Marie-Paule Lefranc, Montpellier, France).

- *RQ-PCR*

Tests for residual disease were conducted by RQ-PCR amplification using TaqMan technology. The PCR was performed in 96-well reaction plates; ABI 7300 was the reference instrument (Applied Biosystems) with germline TaqMan fluorescent probes and clone-specific primers for all identified rearrangements.<sup>6,7</sup> The germline probes/primers and the clone specific primers were designed for each target using the Primer Express (Applied Biosystems) program. The efficiency of our RQ-PCR assay was evaluated by calculating the slope values of the standard curve made by serially diluting the diagnostic DNA specimen in DNA obtained from mononuclear cells (MNC) from a pool of five healthy donors. The serial dilutions ranged from  $10^{-1}$  to  $10^{-5}$  and were tested in triplicate. MRD PCR targets were tested for specificity and sensitivity to select, for each patient, one target with a sensitivity of at least  $10^{-4}$  and a quantitative range of at least  $10^{-4}$ , optimized for each rearrangement tested, both by increasing the annealing temperature and/or designing new primers. For normalization of the quantitative results, ALB - as the reference gene - was always amplified, so that all data were within a certain confidence interval and acceptability. RQ-PCR analyses were performed and interpreted according to the guidelines developed within the “EuroMRD Consortium”.<sup>8</sup>

#### *BCR/ABL1-like predictor*

This tool is based on the quantification of the 9 previously identified transcripts - *SOCS2*, *IFITM1*, *CD99*, *TP53INP1*, *IFITM2*, *IGJ*, *NUTD4*, *CD97*, *SEMA6A* - and of *CRLF2*<sup>9</sup> by Q-RT-PCR (SybrGreen method, QuantStudio5 Real-time PCR System, Thermo Fisher Scientific, Waltham, MA) and expression values were computed as  $2^{(-\Delta Ct)}$ . Patients with a score  $\geq -0.3$  were classified as Ph-like ALL.

#### *Screening of recurrent mutations and deletions*

Sequencing libraries were prepared from 100 ng genomic DNA by using the Truseq custom amplicon kit (Illumina, San Diego, CA). After library quality check, samples were pooled equimolarly and sequenced on an Illumina MiSeq in paired-end reads of 300 bp each by using a MiSeq Reagent Kit v2.

and were analyzed using the Variant Studio Software, considering only variants satisfying the following criteria: i) exonic variants; ii) quality of 100; iii) GQX equal to 100; iv) missense and truncating variants; v) read depth  $>100$ . All variants recognized as single nucleotide

polymorphisms (SNPs) were excluded, unless a prognostic value was previously demonstrated or they were previously reported in Ph-like ALL.<sup>21</sup> Furthermore, SNPs predicted as deleterious by the PolyPhen-2 tool were annotated. Sanger sequencing was also performed to validate selected variants. Exon 6 of *IL7R* was also sequenced by Sanger since the coverage of this hotspot was insufficient and chromatograms were visually inspected for the presence of INDELs by using Mutation Surveyor v4.0.9 (SoftGenetics, State College, PA).

#### *Targeted RNA-sequencing and FISH analysis*

After library quality check, samples were pooled equimolarly and sequenced on an Illumina MiSeq in paired-end reads of 76 bp each by using a MiSeq Reagent Kit v3. Fusion call was performed by using TopHat v1.1 and RNA-sequencing Alignment v2.0 software integrated in BaseSpace Sequence Hub (<https://basespace.illumina.com/apps/>).

DNA clones for *ABL1*, *ABL2*, *CSF1R*, *FGFR1*, *PDGFRB*, *JAK2*, and *TSLP* tyrosin-kinases (TKs) were selected from the genomic databases “Ensembl” (Genome Browser, GRCh37) and “UCSC” (University of California, Santa Cruz, Genome Browser Feb. 2009, GRCh37/hg19), and were labelled by nick translation using spectrum orange and spectrum green dUTP (Abbott Molecular, Chicago, IL) (Supplemental Table 4). *CRLF2* was studied with Zytolight<sup>®</sup> SPEC CRLF2 Dual Color Break Apart Probe (ZytoVision GmbH, Bremerhaven, Germany). A clone for *IL7R* was used as internal control. Analysis was done out using a fluorescence microscope Olympus BX61 (Olympus, Milan, Italy) equipped with a high sensitive camera JAI (Copenhagen, Denmark) and driven by CytoVision 4.5.4 software (Genetix, New Milton, Hampshire, UK). At least 100 interphase nuclei were analyzed in each experiment. A two-step diagnostic workflow was carried out to study first, *CRLF2* and then, in negative cases, the other TKs. Partner genes were investigated in cases with *ABL1* or *PDGFRB* involvement.

## **Supplemental results**

#### *Genetic features of B-NEG ALL cohort*

NGS experiments focused on the most frequently mutated genes of the JAK/STAT and RAS pathway cascades. The median read depth per amplicon was 3467 reads per sample (IQR: 1124–5086), detailed in Supplemental Table 5. Considering the whole cohort, we found 24 JAK/STAT pathway mutations in 16 patients (17%), mainly affecting *JAK2* - mutated in 8 cases (8.8%) - and

*JAK1* - mutated in 6 cases (6.6%). *IL7R*, *JAK3* and *CRLF2* mutations were less common, being documented in 3, 2 and 2 samples, respectively. Subclonal mutations (n=13) accounted for 54.2% of the total.

Overall, we detected a total of 59 RAS pathway mutations in 41 cases (45.1%), with 8 cases displaying >1 mutated gene and 7 cases with >1 mutation targeting the same gene. The most frequently affected genes were *NRAS* and *KRAS* (39 mutations): *NRAS* was mutated in 18 (19.8%) and *KRAS* in 15 (16.5%) cases, *FLT3* proved mutated in 9 samples (9.9%) and *PTPN11* in 8 cases (8.8%). Notably, a considerable proportion of mutations (23/59, 38.9%) were detected at the subclonal level (variant-allele frequency <15%). Lastly, in 9 cases the JAK/STAT and RAS cascades were simultaneously affected.

In the entire B-NEG ALL cohort, we found that the most frequently deleted genes were *CDKN2A/2B*, *IKZF1*, *PAX5* and *BTG1*, in 35 (40.2%), 32 (36.7%), 20 (22.9%) and 17 (19.5%) cases, respectively. Sixty-two % of *IKZF1*-deleted samples were *IKZF1+ CDKN2A/2B and/or PAX5*. The remaining gene deletions were detected in <15% of cases.

## References

1. Pongers-Willemse MJ, Seriu T, Stoltz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. *Leukemia*. 1999;13(1):110-118.
2. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. *Leukemia*. 2003;17(12):2257-2317.
3. Szczepanski T, van der Velden VH, Hoogeveen PG, et al. Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. *Blood*. 2004;103(10):3798-3804.
4. Langerak AW, Szczepański T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. *Leukemia*. 1997;11(12):2192-2199.
5. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood*. 2008;111(12):5477-5485.
6. Brüggemann M, Droese J, Bolz I, et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. *Leukemia*. 2000;14(8):1419-1425.
7. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. *Haematologica*. 2005;90(3):382-390.
8. van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. *Leukemia*. 2007;21(4):604-611.
9. Chiaretti S, Brugnoletti F, Messina M, et al. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. *Leuk Res*. 2016;41:36-42

**Supplemental Table 1.** Clinical feature of the cohort of study.

	<b>Whole B-NEG ALL cohort (n=105)</b>	
<b>Age (median [range])</b>	38.7	[18.2-64.7]
<b>WBC x 10<sup>9</sup>/L (median [range])</b>	5.1	[0.23-347]
<b>Hb g/dL (median [range])</b>	9.4	[3.7-15.7]
<b>Plts x 10<sup>9</sup>/L (median [range])</b>	56	[7.5-630]
<b>Gender (%)</b>		
	<b>M</b>	61 (58.1)
	<b>F</b>	44 (41.9)
<b>Risk (%)</b>		
	<b>Standard risk</b>	62 (64.6)
	<b>No Standard risk</b>	34 (35.4)
<b>CR (%)</b>		
	<b>No CR</b>	13 (12.6)
	<b>CR</b>	90 (87.4)

**Supplemental Table 2.** Clinical feature of the cohort of study in comparison with the whole B-NEG ALL cohort enrolled in the protocol.

	Whole B-NEG cohort enrolled in the protocol (n=115)	Cohort studied for the <i>BCR/ABL1</i> -like predictor (n=88)	p-value
<b>Age (median [range])</b>	39.08 [18.18-64.71]	37.5 [18.18-64.59]	Ns
<b>WBC x 10<sup>9</sup>/L (median [range])</b>	4.72 [0.23-347]	5.62 [0.23-347]	Ns
<b>Hb g/dL (median [range])</b>	9.00 [3.7-15.7]	9.4 [3.7-15.7]	Ns
<b>Plts x 10<sup>9</sup>/L (median [range])</b>	55.5 [7.5-630]	56.5 [7.5-630]	
<b>Gender (%)</b>			
<b>M</b>	67 (58.3)	53 (60.2)	Ns
<b>F</b>	48 (41.7)	35 (39.8)	
<b>Risk (%)</b>			
<b>Standard risk</b>	69 (65.1)	48 (60.8)	Ns
<b>No Standard risk</b>	37	31 (39.2)	
<b>CR (%)</b>			
<b>No CR</b>	14 (12.5)	12 (14.0)	Ns
<b>CR</b>	98 (87.5)	74 (86.0)	

**Supplemental Table 3.** List of the studies performed in each sample and summary of the main genetic features.

Record ID	BCR/ABL1 like predictor	BCR/ABL1 -like prediction	Score	CRLF2 expression	Mutation analysis	RAS pathway status	JAK/STAT pathway status	MLPA analysis	IKZF1	CDKN2A/B	PAX5	IKZF1+CDKN2A and/or PAX5	BTG1	EBF1	CDKN2A/2B and/or RB1	TK/cytokine receptor fusions (RNAseq and/or FISH analysis)
B-ALL_1	Yes	BCR/ABL1 -like	3.073	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	Δ	no-Δ	EBF1-PDGFRB
B-ALL_2	NA				Yes	M clonal	WT	Yes	Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	NA
B-ALL_3	Yes	BCR/ABL1 -like	0.928	Low	Yes	M	WT	Yes	Δ	Δ	Δ	Yes	no-Δ	no-Δ	Δ	No
B-ALL_4	Yes	BCR/ABL1 -like	0.347	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		Δ	no-Δ	Δ	No
B-ALL_5	Yes	non-BCR/ABL1 -like	-1.041	Low	Yes	M clonal	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_6	Yes	non-BCR/ABL1 -like	-1.588	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_7	Yes	BCR/ABL1 -like	1.216	High	Yes	WT	M clonal	Yes	Δ	Δ	no-Δ	Yes	no-Δ	no-Δ	Δ	No
B-ALL_8	NA				Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	NA
B-ALL_9	Yes	non-BCR/ABL1 -like	-0.331	Low	Yes	WT	WT	Yes	Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_10	Yes	non-BCR/ABL1 -like	-1.701	Low	Yes	M clonal	M	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_11	Yes	non-BCR/ABL1 -like	-1.439	Low	Yes	WT	WT	Yes	no-Δ	Δ	Δ		Δ	no-Δ	Δ	No
B-ALL_12	Yes	non-BCR/ABL1 -like	-1.459	High	Yes	WT	WT	Yes	no-Δ	Δ	no-Δ		no-Δ	no-Δ	Δ	No
B-ALL_13	Yes	non-BCR/ABL1 -like	-1.498	Low	NA				NA							No
B-ALL_14	Yes	non-BCR/ABL1 -like	-1.529	Low	Yes	M clonal	WT	Yes	no-Δ	Δ	no-Δ		no-Δ	no-Δ	Δ	No
B-ALL_15	Yes	non-BCR/ABL1 -like	-1.586	Low	Yes	M	WT	Yes	Δ	Δ	no-Δ	Yes	no-Δ	no-Δ	Δ	No
B-ALL_16	Yes	BCR/ABL1 -like	0.788	Low	Yes	WT	WT	Yes	Δ	Δ	Δ	Yes	Δ	no-Δ	Δ	BCR/JAK2
B-ALL_17	Yes	non-BCR/ABL1 -like	-0.720	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_18	Yes	non-BCR/ABL1 -like	-1.416	Low	Yes	M	M	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_19	Yes	non-BCR/ABL1 -like	-0.627	High	Yes	M	WT	Yes	no-Δ	Δ	no-Δ		no-Δ	no-Δ	Δ	No
B-ALL_20	Yes	non-BCR/ABL1 -like	-0.624	Low	Yes	M clonal	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_21	Yes	non-BCR/ABL1 -like	-1.483	Low	Yes	M clonal	WT	Yes	Δ	Δ	Δ	Yes	no-Δ	no-Δ	Δ	No
B-ALL_22	Yes	BCR/ABL1 -like	0.157	Low	Yes	M	WT	Yes	Δ	no-Δ	no-Δ		Δ	no-Δ	Δ	NUP214/ABL1
B-ALL_23	NA				Yes	WT	WT	Yes	Δ	Δ	Δ	Yes	no-Δ	no-Δ	Δ	NA
B-ALL_24	NA				Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	NA
B-ALL_25	Yes	non-BCR/ABL1 -like	-0.600	High	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_26	Yes	BCR/ABL1 -like	3.128	High	Yes	M	M clonal	Yes	Δ	no-Δ	Δ	Yes	no-Δ	Δ	no-Δ	No
B-ALL_27	Yes	non-BCR/ABL1 -like	-1.324	High	NA			NA								No
B-ALL_28	Yes	non-BCR/ABL1 -like	-1.169	Low	Yes	WT	WT	Yes	no-Δ	Δ	Δ		no-Δ	no-Δ	Δ	No
B-ALL_29	Yes	non-BCR/ABL1 -like	-0.999	Low	NA			NA								No
B-ALL_30	NA				Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	NA
B-ALL_31	Yes	BCR/ABL1 -like	2.382	High	Yes	WT	M clonal	Yes	Δ	no-Δ	Δ	Yes	no-Δ	Δ	no-Δ	IGH/CRLF2
B-ALL_32	Yes	BCR/ABL1 -like	5.720	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	NA
B-ALL_33	Yes	non-BCR/ABL1 -like	-1.153	Low	Yes	M clonal	WT	Yes	Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_34	Yes	BCR/ABL1 -like	0.725	Low	Yes	M	WT	Yes	Δ	no-Δ	no-Δ		Δ	no-Δ	no-Δ	NUP214/ABL1
B-ALL_35	Yes	non-BCR/ABL1 -like	-1.295	High	Yes	M clonal	M clonal	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No only by FISH
B-ALL_36	Yes	BCR/ABL1 -like	0.205	High	Yes	WT	M clonal	Yes	Δ	Δ	no-Δ	Yes	no-Δ	no-Δ	Δ	P2RY8/CRLF2
B-ALL_37	Yes	BCR/ABL1 -like	0.386	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		Δ	Δ	no-Δ	No
B-ALL_38	Yes	non-BCR/ABL1 -like	-1.264	Low	Yes	WT	WT	Yes	Δ	Δ	no-Δ	Yes	no-Δ	no-Δ	Δ	No
B-ALL_39	Yes	non-BCR/ABL1 -like	-1.520	Low	Yes	WT	WT	Yes	no-Δ	Δ	no-Δ		no-Δ	no-Δ	Δ	No
B-ALL_40	Yes	non-BCR/ABL1 -like	-1.541	Low	Yes	M clonal	WT	Yes	no-Δ	Δ	no-Δ		no-Δ	no-Δ	Δ	No
B-ALL_41	Yes	BCR/ABL1 -like	0.726	Low	Yes	M	M clonal	Yes	Δ	Δ	no-Δ	Yes	no-Δ	no-Δ	Δ	No
B-ALL_42	NA				Yes	M clonal	WT	Yes	no-Δ	no-Δ	no-Δ		Δ	no-Δ	Δ	NA
B-ALL_43	Yes	non-BCR/ABL1 -like	-0.677	Low	NA			NA								No
B-ALL_44	Yes	BCR/ABL1 -like	1.587	High	Yes	WT	WT	Yes	Δ	no-Δ	Δ	Yes	Δ	no-Δ	Δ	ZC3HAV1/ABL2
B-ALL_45	Yes	BCR/ABL1 -like	0.262	Low	Yes	WT	M clonal	NA								No
B-ALL_46	Yes	BCR/ABL1 -like	2.449	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_47	NA				Yes	M clonal	WT	Yes	Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	NA
B-ALL_48	Yes	non-BCR/ABL1 -like	-1.191	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_49	NA				Yes	M clonal	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	NA
B-ALL_50	Yes	non-BCR/ABL1 -like	-1.417	Low	Yes	M clonal	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_51	Yes	non-BCR/ABL1 -like	-1.537	High	NA			NA								No only by FISH
B-ALL_52	Yes	BCR/ABL1 -like	1.013	Low	Yes	WT	WT	Yes	no-Δ	Δ	Δ		Δ	no-Δ	Δ	No
B-ALL_53	Yes	non-BCR/ABL1 -like	-0.497	Low	Yes	WT	WT	Yes	no-Δ	Δ	Δ		Δ	no-Δ	Δ	No
B-ALL_54	Yes	non-BCR/ABL1 -like	-1.636	Low	Yes	M clonal	WT	Yes	no-Δ	Δ	Δ		no-Δ	no-Δ	Δ	No
B-ALL_55	Yes	BCR/ABL1 -like	0.544	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		Δ	no-Δ	no-Δ	No
B-ALL_56	Yes	non-BCR/ABL1 -like	-1.071	Low	Yes	WT	WT	Yes	Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_57	Yes	non-BCR/ABL1 -like	-1.468	Low	Yes	WT	WT	Yes	no-Δ	no-Δ	no-Δ		no-Δ	no-Δ	no-Δ	No
B-ALL_58	Yes	non-BCR/ABL1 -like	-1.180	Low	Yes	M clonal	WT	Yes	no-Δ	Δ	no-Δ		no-Δ	no-Δ	Δ	No

**Supplemental Table 4.** FISH probes.

		Genomic clones		
Kinase	Mapping	Centromeric	Spanning	Telomeric
<i>ABL2</i>	1q25	RP11-177A2		RP11-345I18
<i>IL7R</i>	5p13	RP11-974M7		
<i>TSLP</i>	5q22		RP11-746A23	
<i>PDGFRB</i>	5q32	LSI PDGFRB Dual Color, Break Apart (Vysis, Abbott)		

<i>CSF1R</i>	5q32	RP11-1000S5		RP11-432O16
<i>FGFR1</i>	8p11	RP11-359P11		RP11-513D5
		RP11-495O10		RP11-265K5
<i>JAK2</i>	9p24	RP11-39K24		RP11-125K10
<i>ABL1</i>	9q34	RP11-57C19		RP11-83J21
<b>Partners</b>				
<i>TNIP1</i>	5q33.1	RP11-915J10		RP11-632E9
<i>EBF1</i>	5q33.3	RP11-1019K12		RP11-583A20
<i>NUP214</i>	9q34	RP11-143H20	RP11-544A12	

**Supplemental Table 5.** Median coverage per sample itemized by amplicon. Amplicons are indicated by chromosome and start/end coordinates according to GRCh37/hg19.

Amplicon ID	Chromosome	Start	End	Median read depth per sample	Target Exon	CCDS
CRLF2 + CRLF2_UserDefined (47131292)_140707109	chrX	1314870	1315034	3188.50	EX6	75945.1
CRLF2 + CRLF2_UserDefined (47229427)_140707061	chrX	1325306	1325512	1763.50	EX3	75945.1
CRLF2 + CRLF2_UserDefined (47229427)_140707062	chrX	1325306	1325512	5066.00	EX3	75945.1
CRLF2_Cds_17104068_UserDefined (47229428)_140707063	chrX	1331429	1331547	6125.00	EX1	75945.1
CRLF2_Cds_17104572_UserDefined (47229425)_140707058	chrX	1317399	1317601	1386.00	EX5	75945.1
CRLF2_Cds_17104572_UserDefined (47229425)_140707059	chrX	1317399	1317601	5341.50	EX5	75945.1
CRLF2_Cds_17104572_UserDefined (47229425)_140707059	chrX	1317399	1317601	272.50	EX5	75945.1
CRLF2_Cds_17105645_UserDefined (47229426)_140707060	chrX	1321252	1321425	97.00	Ex4	75945.1
CRLF2_Cds_17108029_UserDefined (47229374)_140706942	chrX	1327679	1327821	138.50	Ex2	75945.1
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706972	chr13	28608004	28608564	3867.50	EX13,14,15	31953.1
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706973	chr13	28608004	28608564	7544.00	EX13,14,15	31953.1
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706974	chr13	28608004	28608564	8473.00	EX13,14,15	31953.1
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706975	chr13	28608004	28608564	5510.00	EX13,14,15	31953.1
FLT3 + FLT3_UserDefined (47132139)_140706976	chr13	28609612	28610200	1858.50	EX11,12	31953.1
FLT3 + FLT3_UserDefined (47132139)_140706977	chr13	28609612	28610200	2586.50	EX11,12	31953.1
FLT3 + FLT3_UserDefined (47132139)_140706978	chr13	28609612	28610200	4771.50	EX11,12	31953.1
FLT3 + FLT3_UserDefined (47132139)_140706979	chr13	28609612	28610200	4137.00	EX11,12	31953.1
FLT3 + FLT3_UserDefined (47229380)_140706980	chr13	28623501	28623931	379.00	EX7,8	31953.1
FLT3 + FLT3_UserDefined (47229380)_140706981	chr13	28623501	28623931	5173.00	EX7,8	31953.1
FLT3 + FLT3_UserDefined (47229380)_140706982	chr13	28623501	28623931	6367.00	EX7,8	31953.1
FLT3_Cds_16768078_UserDefined (47132129)_140706943	chr13	28611302	28611445	7255.00	EX10	31953.1
FLT3_Cds_16768110_UserDefined (47229408)_140707032	chr13	28622392	28622600	2194.00	EX9	31953.1
FLT3_Cds_16768110_UserDefined (47229408)_140707033	chr13	28622392	28622600	3821.00	Ex9	31953.1
FLT3_Cds_16768173_UserDefined (47229409)_140707034	chr13	28624212	28624379	6360.00	EX6	31953.1
FLT3_Cds_16768912_UserDefined (47131202)_140707037	chr13	28635984	28636226	3693.50	EX3	31953.1
FLT3_Cds_16768912_UserDefined (47131202)_140707038	chr13	28635984	28636226	6962.50	EX3	31953.1
FLT3_Cds_16768942_UserDefined (47229413)_140707040	chr13	28674585	28674667	150.00	Ex1	31953.1
FLT3_Cds_16769202_UserDefined (47229406)_140707030	chr13	28601205	28601398	7894.50	EX17	31953.1
FLT3_Cds_16769656_UserDefined (47229411)_140707036	chr13	28631464	28631619	2173.50	EX4	31953.1
FLT3_Cds_16769738_UserDefined (47229410)_140707035	chr13	28626662	28626831	567.00	EX5	31953.1
FLT3_Cds_16770190_UserDefined (47131204)_140707025	chr13	28589707	28589858	460.50	Ex21	31953.1
FLT3_Cds_16770364_UserDefined (47229412)_140707039	chr13	28644608	28644769	864.00	EX2	31953.1
FLT3_Cds_16770538_UserDefined (47229403)_140707026	chr13	28592584	28592746	5156.50	EX20	31953.1
FLT3_Cds_16770619_UserDefined (47229405)_140707029	chr13	28598978	28599100	127.50	Ex18	31953.1
FLT3_Cds_16770758_UserDefined (47229407)_140707031	chr13	28602295	28602445	244.00	Ex16	31953.1
FLT3_Cds_16772090_UserDefined (47229402)_140707024	chr13	28589274	28589413	6930.50	EX22	31953.1
FLT3_Cds_16772363_UserDefined (47229401)_140707023	chr13	28588569	28588714	1914.00	EX23	31953.1
FLT3_Cds_16773285_UserDefined (47229404)_140707027	chr13	28597467	28597634	4068.50	EX19	31953.1
FLT3_Cds_16773285_UserDefined (47229404)_140707028	chr13	28597467	28597634	6348.50	EX19	31953.1
FLT3_Cds_16773901_UserDefined (47229453)_140707108	chr13	28578172	28578331	7226.00	EX24	31953.1
IL7R_Cds_17002546_UserDefined (47229432)_140707067	chr5	35871138	35871335	2252.00	Ex4	3911.1
IL7R_Cds_17003436_UserDefined (47229431)_140707066	chr5	35867388	35867585	625.50	Ex3	3911.1
IL7R_Cds_17004661_UserDefined (47229430)_140707065	chr5	35860934	35861112	4317.50	Ex2	3911.1
IL7R_Cds_17006734_UserDefined (47229429)_140707064	chr5	35857060	35857181	471.50	Ex1	3911.1
IL7R_Cds_17007143_UserDefined (47229455)_140707115	chr5	35876065	35876605	109.00	Ex8	3911.1
IL7R_Cds_17007143_UserDefined (47229455)_140707116	chr5	35876065	35876605	241.00	Ex8	3911.1
IL7R_Cds_17007143_UserDefined (47229455)_140707117	chr5	35876065	35876605	6207.00	EX8	3911.1
IL7R_Cds_17007407_UserDefined (47229433)_140707068	chr5	35873562	35873770	4700.00	Ex5	3911.1
IL7R_Cds_17007407_UserDefined (47229433)_140707069	chr5	35873562	35873770	6925.50	Ex5	3911.1
IL7R_Cds_17008069_UserDefined (47229434)_140707070	chr5	35874531	35874664	43.50	Ex6	3911.1
IL7R_Cds_17008455_UserDefined (47132221)_140707114	chr5	35875594	35875709	3216.50	EX7	3911.1
JAK1 + JAK1_UserDefined (47131288)_140706987	chr1	65306908	65307304	4772.00	EX17,18	41346.1
JAK1 + JAK1_UserDefined (47131288)_140706988	chr1	65306908	65307304	43.50	EX17,18	41346.1
JAK1_Cds_16667511_UserDefined (47229436)_140707073	chr1	65303595	65303807	5756.00	EX21	41346.1
JAK1_Cds_16667511_UserDefined (47229436)_140707074	chr1	65303595	65303807	2611.00	EX21	41346.1
JAK1_Cds_16668160_UserDefined (47131254)_140707075	chr1	65304128	65304292	2640.50	EX20	41346.1

JAK1_Cds_16668437_UserDefined (47229435)_140707071	chr1	65301059	65301209	1186.50	EX23	41346.1
JAK1_Cds_16668664_UserDefined (47229448)_140707097	chr1	65348940	65349178	2564.00	EX2	41346.1
JAK1_Cds_16668664_UserDefined (47229448)_140707098	chr1	65348940	65349178	3595.00	EX2	41346.1
JAK1_Cds_16668729_UserDefined (47229446)_140707091	chr1	65332529	65332911	7072.00	EX6	41346.1
JAK1_Cds_16668729_UserDefined (47229446)_140707092	chr1	65332529	65332911	6445.50	EX6	41346.1
JAK1_Cds_16668896_UserDefined (47229441)_140707081	chr1	65312312	65312439	1012.50	EX13	41346.1
JAK1_Cds_16669432_UserDefined (47131256)_140707118	chr1	65300228	65300360	4055.50	EX24	41346.1
JAK1_Cds_16669868_UserDefined (47131268)_140707093	chr1	65334974	65335177	3677.50	EX5	41346.1
JAK1_Cds_16669993_UserDefined (47229443)_140707083	chr1	65316467	65316613	4800.50	EX11	41346.1
JAK1_Cds_16670263_UserDefined (47229440)_140707080	chr1	65311176	65311343	709.00	EX14	41346.1
JAK1_Cds_16670566_UserDefined (47131258)_140707089	chr1	65330450	65330675	3741.00	EX7	41346.1
JAK1_Cds_16670566_UserDefined (47131258)_140707090	chr1	65330450	65330675	4244.00	EX7	41346.1
JAK1_Cds_16670758_UserDefined (47229447)_140707094	chr1	65339033	65339226	4466.50	EX4	41346.1
JAK1_Cds_16670758_UserDefined (47229447)_140707095	chr1	65339033	65339226	2156.50	EX4	41346.1
JAK1_Cds_16671022_UserDefined (47229445)_140707087	chr1	65325768	65325965	5669.50	EX8	41346.1
JAK1_Cds_16671022_UserDefined (47229445)_140707088	chr1	65325768	65325965	3150.50	EX8	41346.1
JAK1_Cds_16671238_UserDefined (47229444)_140707084	chr1	65321172	65321401	5527.50	EX10	41346.1
JAK1_Cds_16671238_UserDefined (47229444)_140707085	chr1	65321172	65321401	3457.00	EX10	41346.1
JAK1_Cds_16671455_UserDefined (47229442)_140707082	chr1	65313195	65313378	3702.50	EX12	41346.1
JAK1_Cds_16671565_UserDefined (47229439)_140707079	chr1	65310417	65310592	1402.00	EX15	41346.1
JAK1_Cds_16671602_UserDefined (47131252)_140707072	chr1	65301761	65301918	4786.00	EX22	41346.1
JAK1_Cds_16671956_UserDefined (47229438)_140707078	chr1	65309727	65309918	8625.50	EX22	41346.1
JAK1_Cds_16672003_UserDefined (47229437)_140707076	chr1	65305266	65305498	354.00	EX19	41346.1
JAK1_Cds_16672003_UserDefined (47229437)_140707077	chr1	65305266	65305498	494.50	EX19	41346.1
JAK1_Cds_16672014_UserDefined (47131262)_140707096	chr1	65344688	65344851	2996.50	EX3	41346.1
JAK1_Cds_16672393_UserDefined (47131272)_140707099	chr1	65351922	65351967	2898.00	EX1	41346.1
JAK1_Cds_16672446_UserDefined (47132208)_140707086	chr1	65323319	65323482	3368.50	EX9	41346.1
JAK2 + JAK2_UserDefined (47229375)_140706944	chr9	5080209	5080703	3969.00	EX15,16	6457.1
JAK2 + JAK2_UserDefined (47229375)_140706945	chr9	5080209	5080703	3622.50	EX15,16	6457.1
JAK2 + JAK2_UserDefined (47229375)_140706946	chr9	5080209	5080703	5232.00	EX15,16	6457.1
JAK2 + JAK2_UserDefined (47229449)_140707100	chr9	5126313	5126808	3888.50	EX22,23	6457.1
JAK2 + JAK2_UserDefined (47229449)_140707101	chr9	5126313	5126808	4304.50	EX22,23	6457.1
JAK2 + JAK2_UserDefined (47229449)_140707102	chr9	5126313	5126808	3657.00	EX22,23	6457.1
JAK2 + JAK2_UserDefined (47229454)_140707110	chr9	5090347	5091015	4185.50	EX19,20	6457.1
JAK2 + JAK2_UserDefined (47229454)_140707111	chr9	5090347	5091015	5543.00	EX19,20	6457.1
JAK2 + JAK2_UserDefined (47229454)_140707112	chr9	5090347	5091015	319.50	EX19,20	6457.1
JAK2 + JAK2_UserDefined (47229454)_140707113	chr9	5090347	5091015	4606.00	EX19,20	6457.1
JAK2_Cds_17086073_UserDefined (47229385)_140706993	chr9	5050666	5050851	2780.00	EX4	6457.1
JAK2_Cds_17086073_UserDefined (47229385)_140706994	chr9	5050666	5050851	125.00	EX4	6457.1
JAK2_Cds_17086074_UserDefined (47229393)_140707010	chr9	5089654	5089883	314.00	EX18	6457.1
JAK2_Cds_17086074_UserDefined (47229393)_140707011	chr9	5089654	5089883	2120.00	EX18	6457.1
JAK2_Cds_17086262_UserDefined (47229382)_140706989	chr9	5021968	5022233	1241.50	EX1	6457.1
JAK2_Cds_17086262_UserDefined (47229382)_140706990	chr9	5021968	5022233	6433.50	EX1	6457.1
JAK2_Cds_17087236_UserDefined (47229392)_140707009	chr9	5081705	5081881	178.50	EX17	6457.1
JAK2_Cds_17087477_UserDefined (47229394)_140707012	chr9	5122984	5123141	2337.50	EX21	6457.1
JAK2_Cds_17087554_UserDefined (47229383)_140706991	chr9	5029763	5029926	4415.00	EX2	6457.1
JAK2_Cds_17087712_UserDefined (47229389)_140707003	chr9	5069905	5070072	1260.50	EX10	6457.1
JAK2_Cds_17087860_UserDefined (47132148)_140706998	chr9	5064863	5065060	4233.50	EX7	6457.1
JAK2_Cds_17087860_UserDefined (47132148)_140706999	chr9	5064863	5065060	831.00	EX7	6457.1
JAK2_Cds_17087904_UserDefined (47132154)_140707006	chr9	5077433	5077600	4535.50	EX13	6457.1
JAK2_Cds_17087904_UserDefined (47132154)_140707007	chr9	5077433	5077600	868.50	EX13	6457.1
JAK2_Cds_17088449_UserDefined (47132152)_140707004	chr9	5072472	5072646	2390.50	EX11	6457.1
JAK2_Cds_17088454_UserDefined (47229390)_140707005	chr9	5073678	5073805	4408.50	EX12	6457.1
JAK2_Cds_17088950_UserDefined (47229384)_140706992	chr9	5044383	5044540	7850.00	EX3	6457.1
JAK2_Cds_17089173_UserDefined (47229391)_140707008	chr9	5078286	5078464	2013.00	EX14	6457.1
JAK2_Cds_17089231_UserDefined (47229386)_140706995	chr9	5054543	5054904	711.00	EX5	6457.1
JAK2_Cds_17089231_UserDefined (47229386)_140706996	chr9	5054543	5054904	2713.00	EX5	6457.1
JAK2_Cds_17090261_UserDefined (47132150)_140707001	chr9	5069002	5069228	5903.00	EX9	6457.1
JAK2_Cds_17090261_UserDefined (47132150)_140707002	chr9	5069002	5069228	4175.50	EX9	6457.1
JAK2_Cds_17091284_UserDefined (47229387)_140706997	chr9	5055649	5055808	1269.50	EX6	6457.1
JAK2_Cds_17091671_UserDefined (47229388)_140707000	chr9	5066658	5066809	330.00	Ex8	6457.1
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706967	chr19	17953816	17954729	607.50	EX2,3,4	12366.1


JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706968	chr19	17953816	17954729	1720.50	EX2,3,4	12366.1
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706969	chr19	17953816	17954729	5329.00	EX2,3,4	12366.1
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706970	chr19	17953816	17954729	1962.50	EX2,3,4	12366.1
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706971	chr19	17953816	17954729	5370.00	EX2,3,4	12366.1
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706957	chr19	17945360	17946044	3898.50	EX14,15,16	12366.1
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706958	chr19	17945360	17946044	4453.00	EX14,15,16	12366.1
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706959	chr19	17945360	17946044	6911.50	EX14,15,16	12366.1
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706960	chr19	17945360	17946044	3776.00	EX14,15,16	12366.1
JAK3 + JAK3_UserDefined (47132131)_140706947	chr19	17940897	17941449	88.50	EX21,22	12366.1
JAK3 + JAK3_UserDefined (47132131)_140706948	chr19	17940897	17941449	31.00	EX21,22	12366.1
JAK3 + JAK3_UserDefined (47132131)_140706949	chr19	17940897	17941449	1424.00	EX21,22	12366.1
JAK3 + JAK3_UserDefined (47132133)_140706954	chr19	17943308	17943758	1471.00	EX17,18	12366.1
JAK3 + JAK3_UserDefined (47132133)_140706955	chr19	17943308	17943758	355.50	EX17,18	12366.1
JAK3 + JAK3_UserDefined (47132133)_140706956	chr19	17943308	17943758	1707.00	EX17,18	12366.1
JAK3 + JAK3_UserDefined (47132135)_140706961	chr19	17948721	17949219	7354.50	EX10,11	12366.1
JAK3 + JAK3_UserDefined (47132135)_140706962	chr19	17948721	17949219	4540.50	EX10,11	12366.1
JAK3 + JAK3_UserDefined (47132135)_140706963	chr19	17948721	17949219	5699.00	EX10,11	12366.1
JAK3 + JAK3_UserDefined (47229376)_140706950	chr19	17942017	17942627	3947.50	EX19,20	12366.1
JAK3 + JAK3_UserDefined (47229376)_140706951	chr19	17942017	17942627	626.00	EX19,20	12366.1
JAK3 + JAK3_UserDefined (47229376)_140706952	chr19	17942017	17942627	64.00	EX19,20	12366.1
JAK3 + JAK3_UserDefined (47229376)_140706953	chr19	17942017	17942627	2191.50	EX19,20	12366.1
JAK3 + JAK3_UserDefined (47229378)_140706964	chr19	17952178	17952591	6383.00	EX6,7	12366.1
JAK3 + JAK3_UserDefined (47229378)_140706965	chr19	17952178	17952591	711.50	EX6,7	12366.1
JAK3 + JAK3_UserDefined (47229378)_140706966	chr19	17952178	17952591	572.50	EX6,7	12366.1
JAK3_Cds_16875134_UserDefined (47229397)_140707016	chr19	17953105	17953439	4232.50	EX5	12366.1
JAK3_Cds_16875134_UserDefined (47229397)_140707017	chr19	17953105	17953439	1160.50	EX5	12366.1
JAK3_Cds_16876878_UserDefined (47131220)_140707014	chr19	17947918	17948042	251.50	EX12	12366.1
JAK3_Cds_16877020_UserDefined (47229395)_140707013	chr19	17946713	17946880	397.00	EX13	12366.1
JAK3_Cds_16877924_UserDefined (47132127)_140706939	chr19	17950274	17950639	1674.50	EX9	12366.1
JAK3_Cds_16877924_UserDefined (47132127)_140706940	chr19	17950274	17950639	5601.50	EX9	12366.1
JAK3_Cds_16877924_UserDefined (47132127)_140706941	chr19	17950274	17950639	1461.50	EX9	12366.1
JAK3_Cds_16878504_UserDefined (47229398)_140707018	chr19	17955023	17955246	1238.50	EX1	12366.1
JAK3_Cds_16878504_UserDefined (47229398)_140707019	chr19	17955023	17955246	1417.00	EX1	12366.1
JAK3_Cds_16879644_UserDefined (47229373)_140706938	chr19	17937543	17937924	3472.50	EX23	12366.1
JAK3_Cds_16880177_UserDefined (47229396)_140707015	chr19	17951019	17951170	6106.50	EX8	12366.1
KRAS_Cds_16746132_UserDefined (47229450)_140707104	chr12	25362712	25362865	859.00	Ex4	8702.1
KRAS_Cds_16746135_UserDefined (47132216)_140707105	chr12	25368358	25368514	8414.00	EX4	8703.1
KRAS_Cds_16746575_UserDefined (47229400)_140707021	chr12	25380148	25380366	7348.00	Ex2	8702.1
KRAS_Cds_16746575_UserDefined (47229400)_140707022	chr12	25380148	25380366	6820.00	EX2	8702.1
KRAS_Cds_16746855_UserDefined (47229399)_140707020	chr12	25378528	25378727	1316.00	EX3	8702.1
KRAS_Cds_16749892_UserDefined (47229381)_140706986	chr12	25398188	25398338	2348.00	EX1	8702.1
NRAS_Cds_16673855_UserDefined (47229424)_140707057	chr1	115258651	11525880	5145.50	Ex1	877.1
NRAS_Cds_16676341_UserDefined (47229423)_140707055	chr1	115256401	11525661	758.00	Ex2	877.1
NRAS_Cds_16676341_UserDefined (47229423)_140707056	chr1	115256401	11525661	392.50	Ex2	877.1
NRAS_Cds_16677908_UserDefined (47229422)_140707054	chr1	115252170	11525236	778.00	Ex3	877.1
NRAS_Cds_16678533_UserDefined (47229452)_140707107	chr1	115251139	11525129	4885.00	Ex4	877.1
PTPN11 + PTPN11_UserDefined (47132141)_140706983	chr12	112915435	11291583	5164.50	EX8,9	9163.1
PTPN11 + PTPN11_UserDefined (47132141)_140706984	chr12	112915435	11291583	4770.00	EX8,9	9163.1
PTPN11 + PTPN11_UserDefined (47132141)_140706985	chr12	112915435	11291583	9136.00	EX8,9	9163.1
PTPN11 + PTPN11_UserDefined (47132214)_140707103	chr12	112924259	11292445	4029.50	EX11	9163.1
PTPN11_Cds_16763256_UserDefined (47229418)_140707049	chr12	112910728	11291086	2483.50	EX7	9163.1
PTPN11_Cds_16764105_UserDefined (47229416)_140707043	chr12	112888102	11288833	318.00	EX3	9163.1
PTPN11_Cds_16764105_UserDefined (47229416)_140707044	chr12	112888102	11288833	5040.50	EX3	9163.1

PTPN11_Cds_16764883_UserDefined (47229419)_140707051	chr12	112926227	112926334	5671.50	EX12	9163.1
PTPN11_Cds_16765751_UserDefined (47131242)_140707048	chr12	112893734	112893887	5584.50	EX6	9163.1
PTPN11_Cds_16765752_UserDefined (47131244)_140707050	chr12	112919858	112920029	5056.00	EX10	9163.1
PTPN11_Cds_16766151_UserDefined (47229417)_140707047	chr12	112892348	112892504	3610.50	EX5	9163.1
PTPN11_Cds_16766381_UserDefined (47229414)_140707041	chr12	112856896	112856949	208.00	EX1	9163.1
PTPN11_Cds_16766939_UserDefined (47229451)_140707106	chr12	112942479	112942585	3349.50	EX15	9163.1
PTPN11_Cds_16766945_UserDefined (47131248)_140707045	chr12	112890979	112891211	10530.50	EX4	9163.1
PTPN11_Cds_16766945_UserDefined (47131248)_140707046	chr12	112890979	112891211	637.00	EX4	9163.1
PTPN11_Cds_16767137_UserDefined (47229420)_140707052	chr12	112926808	112926999	3461.00	EX13	9163.1
PTPN11_Cds_16767501_UserDefined (47229421)_140707053	chr12	112939928	112940080	4683.50	EX14	9163.1
PTPN11_Cds_16767914_UserDefined (47229415)_140707042	chr12	112884060	112884222	3707.50	EX2	9163.1


**Supplemental Table 6.** Univariate analyses for CR achievement, considering clinically relevant variables and molecular prognostic markers.

		Univariate analysis for CR	
		OR (95%CI)	p-value
Ph-like vs non-Ph-like		0.265 (0.071-0.921)	0.038
Age		0.995 (0.958-1.033)	0.788
WBC		0.989 (0.977-1)	0.062
Plts		1 (0.994-1.008)	0.924
Hb		1.36 (1.011-1.89)	0.051
F vs M		1.898 (0.589-7.313)	0.306
No SR vs SR		0.311 (0.085-1.059)	0.063
<i>IKZF1+ CDKN2A/2B and/or PAX5 vs IKZF1-only/WT</i>		0.362 (0.101-1.37)	0.119
Cell cycle genes deletion vs WT		1.895 (0.547-7.605)	0.329
RAS clonal vs WT/M subclonal		3.125 (0.757-21.247)	0.158
JAK/STAT clonal vs WT/M subclonal		0.571 (0.12-4.139)	0.515

**Supplemental Figure 1.** Scheme of GIMEMA LAL1913 clinical trial.



**Supplemental Figure 2:** Consort diagram summarizing the biological analyses carried out.



**Supplemental Figure 3:** OS of Ph-like (red line, n=27) vs non-Ph-like (n=59).

